Abstract:Background: Alterations in Mitochondrial DNA methylation (MTDM) exist in many tumors, but their role in breast cancer (BC) development remains unclear. Methods: We analyzed BC patient data by combining scRNA-seq and bulk sequencing. Weighted co-expression network analysis (WGCNA) of TCGA data identified mitochondrial DNA methylation (MTDM)-associated genes in BC. COX regression and LASSO regression were used to build prognostic models. The biological function of MTDM was assessed using various methods, such as signaling pathway enrichment analysis, copynumber karyotyping analysis, and quantitative analysis of the cell proliferation rate. We also evaluated MTDM-mediated alterations in the immune microenvironment using immune microenvironment, microsatellite instability, mutation, unsupervised clustering, malignant cell subtype differentiation, immune cell subtype differentiation, and cell-communication signature analyses. Finally, we performed cellular experiments to validate the role of the MTDM-associated prognostic gene NCAPD3 in BC. Results: In this study, MTDM-associated prognostic models divided BC patients into high/low MTDM groups in TCGA/GEO datasets. The difference in survival time between the two groups was statistically significant (P<0.001). We found that high MTDM status was positively correlated with tumor cell proliferation. We analyzed the immune microenvironment and found that low-MTDM group had higher immune checkpoint gene expression/immune cell infiltration, which could lead to potential benefits from immunotherapy. In contrast, the high MTDM group had higher proliferation rates and levels of CD8+T cell exhaustion, which may be related to the secretion of GDF15 by malignant breast epithelial cells with a high MTDM status. Cellular experiments validated the role of the MTDM-associated prognostic gene NCAPD3 (the gene most positively correlated with epithelial malignant cell proliferation in the model) in BC. Knockdown of NCAPD3 significantly reduced the activity and proliferation of MDA-MB-231 and BCAP-37 cells, and significantly reduced their migration ability of BCAP-37 cell line. Conclusion: This study presented a holistic evaluation of the multifaceted roles of MTDM in BC. The analysis of MTDM levels not only enables the prediction of response to immunotherapy but also serves as an accurate prognostic indicator for patients with BC. These insightful discoveries provide novel perspectives on tumor immunity and have the potentially to revolutionize the diagnosis and treatment of BC.

Mitochondria-localized MBD2c facilitates mtDNA transcription and drug resistance

Mitochondrial miRNA Determines Chemoresistance by Reprogramming Metabolism and Regulating Mitochondrial Transcription.

MBD2 regulates the progression and chemoresistance of cholangiocarcinoma through interaction with WDR5

Mitochondria transcription and cancer

MBD3L2 promotes Tet2 enzymatic activity for mediating 5-methylcytosine oxidation.

A CANCER PERSISTENT DNA REPAIR CIRCUIT DRIVEN BY MDM2, MDM4 (MDMX), AND MUTANT P53 FOR RECRUITMENT OF MDC1 AND 53BP1 TO CHROMATIN

MEF2A, a gene associated with mitochondrial biogenesis, promotes drug resistance in gastric cancer

Targeting Mouse Double Minute 2: Current Concepts in DNA Damage Repair and Therapeutic Approaches in Cancer.

MBD2 Facilitates Tumor Metastasis by Mitigating DDB2 Expression

Silencing Of Mbd1 Reverses Pancreatic Cancer Therapy Resistance Through Inhibition Of Dna Damage Repair

Mitochondrial DNA methylation is a predictor of immunotherapy response and prognosis in breast cancer: scRNA-seq and bulk-seq data insights

N6-methyladenosine-modified circ_0000337 sustains bortezomib resistance in multiple myeloma by regulating DNA repair

Methyl-CpG-binding Domain Protein 3-Like 2 (MBD3L2) Promotes Tet2 Enzymatic Activity for Mediating 5mc Oxidation

MALSU1-mediated regulation of mitochondrial function governs proliferation and doxorubicin resistance in triple-negative breast cancer cells

The c-MYC transcription factor conduces to resistance to cisplatin by regulating MMS19 in bladder cancer cells

Alteration of MDM2 by the Small Molecule YF438 Exerts Antitumor Effects in Triple-Negative Breast Cancer

DMDRMR -Mediated Regulation of m 6 A-Modified CDK4 by m 6 A Reader IGF2BP3 Drives ccRCC Progression

Reduced Mtdna Copy Number Increases the Sensitivity of Tumor Cells to Chemotherapeutic Drugs

XRCC2 repairs mitochondrial DNA damage and fuels malignant behavior in hepatocellular carcinoma

DMDRMR-Mediated Regulation of M6a-Modified CDK4 by M6a Reader IGF2BP3 Drives Ccrcc Progression.

Increased Mtdna Copy Number Promotes Cancer Progression by Enhancing Mitochondrial Oxidative Phosphorylation in Microsatellite-Stable Colorectal Cancer